These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26457976)

  • 41. Characteristics of Maternal-Infant Interaction During Treatment for Opioid Withdrawal.
    Maguire DJ; Taylor S; Armstrong K; Shaffer-Hudkins E; DeBate R; Germain AM; Brooks SS
    Neonatal Netw; 2016; 35(5):297-304. PubMed ID: 27636694
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy.
    Mittal L; Suzuki J
    Subst Abus; 2017; 38(3):261-264. PubMed ID: 26672650
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pregnancy and the Opioid Epidemic.
    Haycraft AL
    J Psychosoc Nurs Ment Health Serv; 2018 Mar; 56(3):19-23. PubMed ID: 29505087
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Opioid use disorder during pregnancy in Tennessee: expediency vs. science.
    Martin PR; Finlayson AJ
    Am J Drug Alcohol Abuse; 2015; 41(5):367-70. PubMed ID: 26186388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates.
    Winklbaur B; Kopf N; Ebner N; Jung E; Thau K; Fischer G
    Addiction; 2008 Sep; 103(9):1429-40. PubMed ID: 18783498
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neonatal abstinence syndrome: treatment and pediatric outcomes.
    Logan BA; Brown MS; Hayes MJ
    Clin Obstet Gynecol; 2013 Mar; 56(1):186-92. PubMed ID: 23314720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy.
    ;
    Obstet Gynecol; 2012 May; 119(5):1070-6. PubMed ID: 22525931
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research.
    Jones HE; Chisolm MS; Jansson LM; Terplan M
    Addiction; 2013 Feb; 108(2):233-47. PubMed ID: 22471668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy.
    Liu AJ; Jones MP; Murray H; Cook CM; Nanan R
    Aust N Z J Obstet Gynaecol; 2010 Jun; 50(3):253-8. PubMed ID: 20618243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of a Nurse-Led Program for Rural Pregnant Women With Opioid Use Disorder to Improve Maternal-Neonatal Outcomes.
    Paterno MT; Jablonski L; Klepacki A; Friedmann PD
    J Obstet Gynecol Neonatal Nurs; 2019 Sep; 48(5):495-506. PubMed ID: 31374181
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a substance abuse program for opioid-dependent nonurban pregnant women improves outcome.
    Meyer M; Benvenuto A; Howard D; Johnston A; Plante D; Metayer J; Mandell T
    J Addict Med; 2012 Jun; 6(2):124-30. PubMed ID: 22517450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The MATernaL and Infant NetworK to Understand Outcomes Associated with Treatment of Opioid Use Disorder During Pregnancy (MAT-LINK): Surveillance Opportunity.
    Tran EL; Kim SY; England LJ; Green C; Dang EP; Broussard CS; Fehrenbach N; Hudson A; Yowe-Conley T; Gilboa SM; Meaney-Delman D
    J Womens Health (Larchmt); 2020 Dec; 29(12):1491-1499. PubMed ID: 33227221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medication-assisted treatment with buprenorphine: assessing the evidence.
    Thomas CP; Fullerton CA; Kim M; Montejano L; Lyman DR; Dougherty RH; Daniels AS; Ghose SS; Delphin-Rittmon ME
    Psychiatr Serv; 2014 Feb; 65(2):158-70. PubMed ID: 24247147
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis.
    Link HM; Jones H; Miller L; Kaltenbach K; Seligman N
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100179. PubMed ID: 33345863
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do people with opioid use disorder and posttraumatic stress disorder benefit from dding Individual opioid Drug Counseling to buprenorphine?
    McHugh RK; Hilton BT; Chase AM; Griffin ML; Weiss RD
    Drug Alcohol Depend; 2021 Nov; 228():109084. PubMed ID: 34607194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations.
    Krans EE; Cochran G; Bogen DL
    Clin Obstet Gynecol; 2015 Jun; 58(2):370-9. PubMed ID: 25775440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
    Holbrook AM
    Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Buprenorphine as opioid substitution to pregnant addicts].
    Rasmussen ET; Nielsen LB
    Ugeskr Laeger; 2003 Sep; 165(38):3607-8. PubMed ID: 14556390
    [No Abstract]   [Full Text] [Related]  

  • 60. The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care.
    Pryor JR; Maalouf FI; Krans EE; Schumacher RE; Cooper WO; Patrick SW
    Arch Dis Child Fetal Neonatal Ed; 2017 Mar; 102(2):F183-F187. PubMed ID: 28073819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.